NCT05448820

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

A Phase 1/2 Study of YH001 in Combination With Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Tracon Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma, followed by Phase 2 cohorts of patients with select histologies of advanced or metastatic sarcoma.

Conditions

• Advanced Sarcoma
• Metastatic Sarcoma
• Soft Tissue Sarcoma

Interventions

Type	Name	Description
DRUG	YH001	Anti-CTLA4 antibody
DRUG	Envafolimab	Anti-PD-L1 antibody
DRUG	Doxorubicin	Anthracycline

Timeline

• Start date: 2022-11-14
• Primary completion: 2023-11-01
• Completion: 2025-09-01
• First posted: 2022-07-07
• Last updated: 2023-09-21

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study